Dacomitinib monohydrateProduct ingredient for Dacomitinib

Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains.²

Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.¹⁴ Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model¹, although further investigations are needed.